IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinase-like orphan receptor 1 (ROR1) molecules for their therapeutic potential against sarcomas. Here, we report that IGF1R (15/15) and ROR1 (11/15) were highly expressed in sarcoma cell lines including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma. IGF1R and ROR1 CAR T cells derived from eight healthy donors using the Sleeping Beauty (SB) transposon system were cytotoxic against sarcoma cells and produced high levels of IFN-γ, TNF-α and IL-13 in an antigen-specific manner. IGF1R and ROR1 CAR T cells generated from three sarcoma patients released significant amounts of IFN-γ in response to sarcoma stimulation. The adoptive transfer of IGF1R and ROR1 CAR T cells derived from a sarcoma patient significantly reduced tumor growth in pre-established, systemically disseminated and localized osteosarcoma xenograft models in NSG mice. Infusion of IGF1R and ROR1 CAR T cells also prolonged animal survival in a localized sarcoma model using NOD/scid mice. Our data indicate that both IGF1R and ROR1 can be effectively targeted by SB modified CAR T cells and that such CAR T cells may be useful in the treatment of high risk sarcoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The preclinical study conducted by Huang et al. demonstrated that IGF1R and ROR1 CAR-T cells exhibited significantly tumor growth inhibition and survival extension on sarcoma [127].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 4×
“Recent Phase I clinical trials with CD19-targeted, 2 generation of chimeric antigen receptor (CAR) T cells containing 4-1BB signaling domain have shown a complete remission (CR) rate of>86% in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [3].”
BackgroundInfluentialChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632 · cited 1×
“In sarcomas, ACT with NY-ESO-1 TCR has demonstrated objective clinical responses in four of six patients with synovial cell sarcoma [8].”
BackgroundPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116 · cited 3×
“Therefore, successful targeting IGF1R has a broad impact on cancer treatment [17, 42, 43].”
BackgroundAhmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703 · cited 1×
“First, they directly and specifically kill IGF1R cancer cells even at a low level of surface expression as CD8 CTLs are capable of responding to a single antigen molecule [48].”
BackgroundAntibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614 · cited 2×
“Type I insulin-like growth factor receptor (IGF1R) is expressed in a wide range of solid tumors and hematologic malignancies [15, 16].”
BackgroundAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595 · cited 1×
“ACT including tumor infiltrating lymphocytes (TILs) or T cells engineered with tumor antigen-specific T cell receptors (TCRs) have achieved an objective response rate of approximately 70% in metastatic melanoma [2].”
BackgroundHudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Self-citationThe Type 1 Insulin-Like Growth Factor Receptor Pathway
Chitnis, M. M., Yuen, J. S. P., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4879 · Cited by 445
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403 · cited 1×
“Adoptive T-cell therapy (ACT) is a promising cancer treatment [1].”
BackgroundPappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K.-P., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0000 · Cited by 322
Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J. E., Widhopf, G. F., Rassenti, L. Z., Cantwell, M. J., Prussak, C. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712148105 · Cited by 312 · cited 1×
“ROR1 has been shown to play a role in tumor cell migration and invasiveness and is not usually expressed in normal adult tissues except for B-cell precursors and adipose [22, 26, 31, 32].”
BackgroundHudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266 · cited 3×
“ROR1 has been shown to play a role in tumor cell migration and invasiveness and is not usually expressed in normal adult tissues except for B-cell precursors and adipose [22, 26, 31, 32].”
BackgroundSelf-citationROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Zhang, S., Chen, L., Cui, B., Chuang, H.-Y., Yu, J., Wang-Rodriguez, J., Tang, L., Chen, G., Basak, G. W., & Kipps, T. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031127 · Cited by 260
Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
Baskar, S., Kwong, K. Y., Hofer, T., Levy, J. M., Kennedy, M. G., Lee, E., Staudt, L. M., Wilson, W. H., Wiestner, A., & Rader, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1823 · Cited by 238
Self-citationAhmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Sachdev, D., Li, S. L., Hartell, J. S., Fujita‐Yamaguchi, Y., Miller, J. S., & Yee, D. (2003) · PubMed · Cited by 211
Self-citationJuergens, H., Daw, N. C., Geoerger, B., Ferrari, S., Villarroel, M., Aerts, I., Whelan, J., Dirksen, U., Hixon, M. L., Yin, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0670 · Cited by 211
CAR T Cells for Solid Tumors: Armed and Ready to Go?
Kakarla, S., & Gottschalk, S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 190 · cited 1×
“CAR T cells targeting vascular endothelial growth factor receptor 2 (VEGFR2), epidermal growth factor receptor variant III (EGFRvIII), and mesothelin are being tested in patients with glioblastoma, pancreatic, ovarian and mesothelioma cancers [7].”
BackgroundTargeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis
Cui, B., Zhang, S., Chen, L., Yu, J., Widhopf, G. F., Fecteau, J.-F., Rassenti, L. Z., & Kipps, T. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3832 · Cited by 187 · cited 1×
“ROR1 has been shown to play a role in tumor cell migration and invasiveness and is not usually expressed in normal adult tissues except for B-cell precursors and adipose [22, 26, 31, 32].”
BackgroundOvarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
Zhang, S., Cui, B., Lai, H., Liu, G., Ghia, E. M., Widhopf, G. F., Zhang, Z., Wu, C. C. N., Chen, L., Wu, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419599111 · Cited by 186
Langer, C. J., Novello, S., Park, K., Krzakowski, M., Karp, D. D., Mok, T., Benner, R. J., Scranton, J. R., Olszanski, A. J., & Jassem, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4932 · Cited by 179
Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
Yee, D. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs258 · Cited by 177 · cited 1×
“Several potential mechanisms exist by which tumors are resistant to IGF1R mabs, including downregulation of IGF1R, upregulation of insulin receptor (IR)-A and IGF-I and IGF-II, activation of MAPK/ERK or mTOR pathways, IGF1R-HER2 heterodimerization, and expression of other growth factor receptors [42, 47].”
BackgroundSelf-citationMalempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., Reid, J. M., Schmechel, S., Voss, S. D., Cho, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4355 · Cited by 176
Yee, D., Favoni, R. E., Lebovic, G. S., Lombana, F., Powell, D. R., Reynolds, C. P., & Rosen, N. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114910 · Cited by 175 · cited 1×
“Type I insulin-like growth factor receptor (IGF1R) is expressed in a wide range of solid tumors and hematologic malignancies [15, 16].”
BackgroundSelf-citationSafety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 173 · cited 1×
“Our future work will be focused on assessment of on-target toxicity by IGF1R CAR T cells in animal models and reexamination of ROR1 expression in adult normal tissues although ROR1 CAR T cells have recently shown to be safe in nonhuman primates [53].”
BackgroundSelf-citationBicocca, V. T., Chang, B. H., Masouleh, B. K., Muschen, M., Loriaux, M. M., Druker, B. J., & Tyner, J. W. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.027 · Cited by 170
Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165 · cited 1×
“T cells cultured for 1–3 months were used for assays and were phenotypically effector memory T cells with variable ratios of CD4/CD8 subsets and stable expression of transgenes due to SB-mediated integration as we previously described [38, 41].”
MethodSelf-citationHuang, X., Guo, H., Kang, J., Choi, S., Zhou, T. C., Tammana, S., Lees, C. J., Li, Z.-Z., Milone, M. C., Levine, B. L., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300404 · Cited by 157 · cited 13×
“The scFv, a CD8α hinge and transmembrane domain, and intracellular domains of 4-1BB and CD3z were assembled as IGF1R or ROR1 CARs based on the CTL019 construct provided by Dr. Carl June (University of Pennsylvania) [38].”
MethodInfluentialSelf-citationOwen, L. A., Kowalewski, A. A., & Lessnick, S. L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001965 · Cited by 155 · cited 2×
“Sarcoma cell lines Rh36, Rh41 and OS17 were provided by Dr. Peter Houghton (Nationwide Children's Hospital, Columbus, OH); lines Rh1, Rh18, Rh30, Rh41, U2OS, SaOS2, RD, and HT1080 were provided by Dr. David Largaespada (University of Minnesota, Minneapolis, MN); RD, U2OS, SaOs2 and HT1080 were purchased from ATCC; Rh1…”
BackgroundKailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., Titze, U., Leuchte, K., Landmeier, S., Hotfilder, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.57 · Cited by 142
Huang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2778 · Cited by 127
Xue, X., Huang, X., Nodland, S. E., Mátés, L., Ma, L., Izsvák, Z., Ivics, Z., LeBien, T. W., McIvor, R. S., Wagner, J. E., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210005 · Cited by 126
Self-citationSachdev, D., Singh, R., Fujita-Yamaguchi, Y., & Yee, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3126 · Cited by 117 · cited 2×
“We have previously shown that a chimeric scFv against IGF1R can downregulate IGF1R in breast cancer cells, a general mechanism in antibody resistance [33].”
BackgroundMethodSelf-citationThe receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy
Hojjat‐Farsangi, M., Moshfegh, A., Daneshmanesh, A. H., Khan, A. S., Mikaelsson, E., Österborg, A., & Mellstedt, H. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.005 · Cited by 104 · cited 1×
“Upon ligand binding, ROR1 dimerizes and recruits canonical and non-canonical signaling pathways for cell survival and invasion [51].”
BackgroundYang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A., & Rader, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021018 · Cited by 96
Self-citationLuo, W., Gangwal, K., Sankar, S., Boucher, K. M., Thomas, D., & Lessnick, S. L. (2009) · Oncogene · doi:10.1038/onc.2009.262 · Cited by 93
Broome, H. E., Rassenti, L. Z., Wang, H., Meyer, L., & Kipps, T. J. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.06.021 · Cited by 81
Cj, O., & Chan, S. H. (1990) · PubMed · Cited by 81
Disis, M. L., Gad, E. A., Herendeen, D. R., Phan-Lai, V., Park, K. H., Cecil, D. L., O'Meara, M. M., Treuting, P. M., & Lubet, R. A. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0182 · Cited by 72 · cited 1×
“Furthermore, a multiantigen vaccine targeting Neu, IGFBP-2 and IGF1R was highly effective at preventing tumor progression in mice with preinvasive breast disease, whereas an individual vaccine was partially effective [45].”
BackgroundTargeting malignant B cells with an immunotoxin against ROR1
Baskar, S., Wiestner, A. U., Wilson, W. H., Pastan, I. H., & Rader, C. M. (2012) · mAbs · doi:10.4161/mabs.19870 · Cited by 68 · cited 3×
“Anti-IGF1R and anti-ROR1 scFv sequences were derived from mouse mab 1H7 [34, 39] and 2A2 [24], respectively.”
BackgroundSelf-citationDave, H., Anver, M. R., Butcher, D. O., Brown, P., Khan, J. I., Wayne, A. S., Baskar, S., & Rader, C. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052655 · Cited by 58 · cited 1×
“ROR1 has been shown to play a role in tumor cell migration and invasiveness and is not usually expressed in normal adult tissues except for B-cell precursors and adipose [22, 26, 31, 32].”
BackgroundSelf-citationGattenlöhner, S., Marx, A., Markfort, B., Pscherer, S., Landmeier, S., Juergens, H., Müller–Hermelink, H., Matthews, I., Beeson, D., Vincent, A. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0542 · Cited by 51
Zhou, X., Jun, D. Y., Thomas, A. M., Huang, X., Huang, L., Mautner, J., Mo, W., Robbins, P. F., Pardoll, D. M., & Jaffee, E. M. (2005) · Cancer Research · doi:10.1158/0008-5472.1079.65.3 · Cited by 45
Self-citationCecil, D. L., Park, K. H., Gad, E. A., Childs, J. S., Higgins, D. M., Plymate, S. R., & Disis, M. L. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2577-z · Cited by 21 · cited 1×
“The magnitude of Th2 immunity against predicted T-helper epitopes derived from the IGF1R was also greater in breast cancer patients [44].”
BackgroundMolecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes
Anders, K., & Blankenstein, T. J. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3017 · Cited by 12
Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
Wagner, M. J., & Maki, R. G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00009 · Cited by 11 · cited 2×
“Therefore, successful targeting IGF1R has a broad impact on cancer treatment [17, 42, 43].”
BackgroundKusada, Y., Morizono, T., Matsumoto-Takasaki, A., Sakai, K., Sato, S., Asanuma, H., Takayanagi, A., & Fujita‐Yamaguchi, Y. (2007) · The Journal of Biochemistry · doi:10.1093/jb/mvm192 · Cited by 10 · cited 1×
“Anti-IGF1R and anti-ROR1 scFv sequences were derived from mouse mab 1H7 [34, 39] and 2A2 [24], respectively.”
Cited by
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
“An adoptive transfer of IGFR1-CAR and ROR1-CAR T cells derived from a sarcoma patient significantly suppressed tumor growth in both localized and disseminated sarcoma xenograft models [153].”
BackgroundEwing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The preclinical study conducted by Huang et al. demonstrated that IGF1R and ROR1 CAR-T cells exhibited significantly tumor growth inhibition and survival extension on sarcoma [127].”
Method
Metadata
- Authors
- Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., Rader, C., Hamby, C. V., Loeb, D. M., Cairo, M. S., & Zhou, X.
- Affiliations
- New York Medical College (US)
- University of Minnesota (US)
- Johns Hopkins University (US)
- Scripps Research Institute (US)
- Corresponding author
- Zhou, Xianzheng
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-14
- Volume
- 10
- Issue
- 7
- Pages
- e0133152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4501840
- OpenAlex
- W925209273
- Cited by
- 109
- References
- 54
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 10 · 2023: 16 · 2022: 10 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 3
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R21AI092220, AI092220)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- chimeric antigen receptor T cells, IGF-1 receptor, ROR1, sarcoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, fibrosarcoma, Sleeping Beauty transposon, adoptive T cell therapy, tumor xenograft models, cytokine production, high-risk sarcoma
- MeSH terms
- Animals, Bone Neoplasms, DNA Transposable Elements, Humans, Interferon-gamma, Receptors, Antigen, T-Cell, Sarcoma, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Interferon-alpha, Receptors, Somatomedin, Receptor, IGF Type 1, Interleukin-13, Adoptive Transfer, K562 Cells, Cell Line, Tumor, Mice, Receptor Tyrosine Kinase-like Orphan Receptors, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.